Trial Profile
Open Label Interventional Multicenter Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Successfully Completed the Phase 2 or Phase 3 Studies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms EXOSKEL
- Sponsors Sanofi Genzyme
- 04 Aug 2021 Status changed from active, no longer recruiting to completed.
- 27 May 2021 Planned primary completion date changed from 1 Sep 2020 to 22 Jun 2021.
- 28 Jan 2020 Status changed from recruiting to active, no longer recruiting.